Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label itacitinib study in previously treated myelofibrosis
2020-003123-42Phase 2Terminated
- Sponsor
- Incyte
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of itacitinib in primary myelofibrosis (PMF) and secondary myelofibrosis (SMF) (2 arms), sponsored by Incyte. Primary endpoint: Part 1 safety and tolerability. Started Jan 2021; status: terminated.
02
Drugs
itacitinib
03
Conditions
primary myelofibrosis (PMF)secondary myelofibrosis (SMF)
Beyond the preview
Go deeper on 2020-003123-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003123-42.